LFWD
Lifeward Ltd.
Healthcare · Medical Devices · NCM
$7.01
Data: 2026-05-15
✓ ETHICAL PASS

MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$18M
Total market value of the company
Trailing P/E
N/A
Forward P/E
-5.14
Based on estimated future earnings — lower means cheaper
Rev Growth
-32.7%
Year-over-year revenue change
Profit Margin
-90.4%
How much profit the company keeps from each dollar of revenue
ROE
-146.1%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$20.00
+186% from current price — median analyst estimate
Recommendation
NONE
Consensus view from 2 analysts covering this stock
About Lifeward Ltd.

Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals' post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.

https://golifeward.com

Country: Israel Employees: 81 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
23.9% PASS
Debt must be below 33% of total assets
Cash Ratio
11.8% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime
MARKDOWN
Price trending down — defensive positioning
Sharpe Ratio
-0.594
Returns do not compensate for the risk — negative edge
Kelly Fraction
-0.0989
No positive edge detected — the data suggests staying out
Calmar Ratio
-0.707
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-64.9%
Historical annualised return based on price data
Max Drawdown
-91.8%
Largest peak-to-trough decline — the worst it has been
HMM State
BULL
Statistical model sees bullish momentum
Days in State
1
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

Beta
0.33
Very low correlation to market moves
52W High
$15.84
56% below the year high
52W Low
$4.14
69% above the year low
Avg Volume
15,656
Average daily shares traded — higher means easier to buy and sell
Short Ratio
17.8
Days it would take all short sellers to cover — higher means more crowded
Short % Float
5.1%
Moderate short interest
Div Yield
0.0%
Annual dividend as a percentage of the share price
EPS (TTM)
$-17.16
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity
0.52
Moderate leverage — manageable
Current Ratio
1.31
Adequate but worth monitoring
Quick Ratio
0.69
Like current ratio but excludes inventory — stricter test
Gross Margin
38.2%
Revenue left after cost of goods — higher means pricing power
Operating Margin
-112.7%
Profit from core operations before interest and tax
Free Cash Flow
$-9,717,875
Negative — the business is spending more than it generates
Revenue (TTM)
$22M
Total revenue over the last 12 months
Net Income
$-19,914,000
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
2
Target High
$30.00
Target Median
$20.00
Target Low
$10.00
Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date Insider Title Type Shares Value
2026-05-01 ROSE KEITH DALE Officer 15,000 —
2026-03-25 REZNICK YEHUDA Director 7,657 —
2026-03-25 ROZENBAUM MOSHE H Director 11,485 —
2026-03-25 SIGSBEE WILLIAM MARK Director 11,485 —
2026-03-25 KIDRON NADAV Director 7,657 —
2026-03-25 KIDRON MIRIAM Director 7,657 —
2025-12-11 LYNCH JEANNINE Officer 50,000 —
2025-09-02 LYNCH JEANNINE Officer 1,591 $1,018
2025-08-01 LEVY HADAR Director 35,920 —
2025-08-01 SWINFORD MICHAEL Director 35,920 —
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.